US Senate Passes Eliminate Colorectal Cancer Act

Publication
Article
OncologyONCOLOGY Vol 16 No 10
Volume 16
Issue 10

The US Senate Health, Education, Labor, and Pensions Committee has passed the Eliminate Colorectal Cancer Act (S.710), legislation introduced by Sen. Jesse Helms (R-NC) and Sen. Edward M. Kennedy (D-Mass). The bill, with the companion

The US Senate Health, Education, Labor, and Pensions Committeehas passed the Eliminate Colorectal Cancer Act (S.710), legislation introducedby Sen. Jesse Helms (R-NC) and Sen. Edward M. Kennedy (D-Mass). The bill, withthe companion HR 1520 being mulled by the US House of Representatives, wouldrequire all private health insurance plans to cover colon cancer screeningaccording to scientific guidelines for patients age 50 and over and for othersat high risk of developing the disease.

In a statement, the American Cancer Society noted, "It isup to Congress to ensure that the barriers to life-saving colon cancerscreenings tests are removed. . . The bottom line is that this Act can helpprolong lives and prevent the pain and anguish cancer causes."

Articles in this issue
Capecitabine in the Treatment of Advanced Breast Cancer
Current and Planned Trials With Capecitabine in Adjuvant/Neoadjuvant Therapy of Breast Cancer
Single-Agent vs Combination Therapy in Advanced Breast Cancer: Potential Roles of Capecitabine
Capecitabine and Docetaxel in Advanced Breast Cancer: Analyses of a Phase III Comparative Trial
New Directions With Capecitabine Combinations in Advanced Breast Cancer
Anastrozole Approved for Use in Early Breast Cancer
US Senate Passes Eliminate Colorectal Cancer Act
Cigarette Smoking Among Adults United States, 2000
FDA Approves Kytril for Postoperative Nausea and Vomiting
Optimal Use of Antiemetics in the Outpatient Setting
NIH, Drug Industry Target Barriers to Patient Accrual in Clinical Trials
Medicare Puts PET for Thyroid Cancer, Soft-Tissue Sarcoma on Hold
Investigators Question Effect of Race on Prostate Cancer Survival
Capecitabine With Docetaxel Demonstrates Survival Advantage in Breast Cancer Patients
Use of Fulvestrant for Advanced Breast Cancer Supported by Pivotal Phase III Data
Recent Videos
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
Related Content
Data from the PANOVA-3 trial may support the concomitant use of TTFields plus standard of care in solid tumors across different therapeutic settings.

TTFields Combo Shows Meaningful Benefits in Pancreatic Adenocarcinoma

Russ Conroy
August 7th 2025
Article

Data from the PANOVA-3 trial may support the concomitant use of TTFields plus standard of care in solid tumors across different therapeutic settings.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Phase 2 CRDF-004 results revealed that the addition of onvansertib to chemotherapy/bevacizumab was well-tolerated, with no unexpected toxicities observed.

Onvansertib Exhibits Encouraging Responses in RAS-Mutant Metastatic CRC

Roman Fabbricatore
July 30th 2025
Article

Phase 2 CRDF-004 results revealed that adding onvansertib to chemotherapy/bevacizumab was well tolerated, with no unexpected toxicities observed.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.

EC Approves Cabozantinib Monotherapy in Previously Treated pNET/epNET

Tim Cortese
July 25th 2025
Article

Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.

Radiotherapy Plus Sintilimab and Chemotherapy Improves pCR in Rectal Cancer

Radiotherapy Plus Sintilimab and Chemotherapy Improves pCR in Rectal Cancer

Tim Cortese
July 20th 2025
Article

Short-course radiotherapy combined with sintilimab plus oxaliplatin-capecitabine yielded a pCR rate of 59.2% vs 32.7% with the control arm in locally advanced rectal cancer.